Abstract
Introduction
CD4+CD25+Foxp3+ regulatory T (Treg) cell dysfunction has been documented in various autoimmune disorders, but not in antiphospholipid syndrome (APS) so far.
Methods
In this cross-sectional study, we aim to investigate CD4+CD25+Foxp3+ Treg cells, CD3+CD19− T cells and CD3−CD19+ B cells in patients with primary APS and healthy controls. Cell subtypes were immunophenotyped using specific monoclonal antibodies (anti-CD3 CY5, anti-CD4 FITC, anti-CD25, anti-Foxp3, anti-CD19 PE) and flow cytometry.
Results
Twenty patients with APS and 20 age- and sex-matched controls were studied. The percentage of total lymphocytes, activated Th cells (CD4+CD25+), Treg cells and CD3−CD19+ B cells were found significantly lower in APS patients as compared to controls (all p < 0.05).
Conclusion
A dysfunction in CD4+CD25+Foxp3+ Treg cells may represent one of the mechanisms leading to autoimmunity in APS patients. The decreased number of CD3−CD19+ B cells of APS patients warrants further elucidation.
References
Palomo IG, Segovia FM, Alarcon ML, Fuentes BY, Pereira JG, Rojas A, et al. An insight into the pathophysiology of thrombosis in antiphospholipid syndrome. Front Biosci. 2007;12:3093–103.
López-Pedrera C, Buendía P, Aguirre MA, Velasco F, Cuadrado MJ. Antiphospholipid syndrome and tissue factor: a thrombotic couple. Lupus. 2006;15:161–6.
Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev. 2006;212:8–27.
Yamaguchi T, Wing JB, Sakaguchi S. Two modes of immune suppression by Foxp3(+) regulatory T cells under inflammatory or non-inflammatory conditions. Semin Immunol. 2011;23:424–30.
Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:330–6.
Valencia X, Lipsky PE. CD4+CD25+FoxP3+ regulatory T cells in autoimmune diseases. Nat Clin Pract Rheumatol. 2007;3:619–26.
D’Hennezel E, Bin Dhuban K, Torgerson T, Piccirillo C. The immunogenetics of immune dysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet. 2012;49:291–302.
Peterson RA. Regulatory T-cells: diverse phenotypes integral to immune homeostasis and suppression. Toxicol Pathol. 2012;40:186–204.
Bernard F, Romano A, Granel B. Regulatory T cells and systemic autoimmune diseases: systemic lupus erythematosus, rheumatoid arthritis, primary Sjögren’s syndrome. Rev Med Interne. 2010;31:116–27.
Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.
Moon HW, Kim BH, Park CM, Hur M, Yun YM, Kim SY, Lee MH. CD4+CD25highFoxP3+ regulatory T-cells in hematologic diseases. Korean J Lab Med. 2011;31(4):231–7.
Willis R, Harris EN, Pierangeli SS. Pathogenesis of the antiphospholipid syndrome. Semin Thromb Hemost. 2012;38:305–21.
Meroni PL, Gerosa M, Raschi E, Scurati S, Grossi C, Borghi MO. Updating on the pathogenic mechanisms 5 of the antiphospholipid antibodies-associated pregnancy loss. Clin Rev Allergy Immunol. 2008;34:332–7.
Loser K, Beissert S. Regulatory T cells: banned cells for decades. J Invest Dermatol. 2012;132(3 Pt 2):864–71.
Gómez-Puerta JA, Martín H, Amigo MC, Aguirre MA, Camps MT, Cuadrado MJ, et al. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus? Medicine (Baltimore). 2005;84:225–30.
Genre J, Errante PR, Kokron CM, Toledo-Barros M, Câmara NO, Rizzo LV. Reduced frequency of CD4(+)CD25(HIGH)FOXP3(+) cells and diminished FOXP3 expression in patients with Common Variable Immunodeficiency: a link to autoimmunity? Clin Immunol. 2009;132:215–21.
Hoehlig K, Shen P, Lampropoulou V, Roch T, Malissen B, O’Connor R, et al. Activation of CD4+Foxp3+ regulatory T cells proceeds normally in the absence of B cells during EAE. Eur J Immunol. 2012;42:1164–73.
Kuhn A, Beissert S, Krammer PH. CD4(+)CD25 (+) regulatory T cells in human lupus erythematosus. Arch Dermatol Res. 2009;301:71–81.
Alunno A, Bartoloni E, Bistoni O, Nocentini G, Ronchetti S, Caterbi S, et al. Balance between Regulatory T and Th17 cells in systemic Lupus Erythematosus: the old and the new. Clin Dev Immunol. 2012;2012:823085.
Chen RL, Tao Y, Qiu KW, Huang WH, Huang CH, Li J. Association of circulating Treg cells with disease activity in patients with rheumatoid arthritis. Nan Fang Yi Ke Da Xue Xue Bao. 2012;32(6):886–9.
Torres-Aguilar H, Blank M, Kivity S, Misgav M, Luboshitz J, Pierangeli SS, et al. Tolerogenic dendritic cells inhibit antiphospholipid syndrome derived effector/memory CD4+ T cell response to β2GPI. Ann Rheum Dis. 2012;71:120–8.
Thompson JA, Perry D, Brusko TM. Autologous regulatory T cells for the treatment of type 1 diabetes. Curr Diab Rep. 2012. [Epub ahead of print].
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dal Ben, E.R.R., do Prado, C.H., Baptista, T.S.A. et al. Decreased Levels of Circulating CD4+CD25+Foxp3+ Regulatory T Cells in Patients with Primary Antiphospholipid Syndrome. J Clin Immunol 33, 876–879 (2013). https://doi.org/10.1007/s10875-012-9857-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10875-012-9857-y